Forgot your password?
dydo, October 18 in Solid Biosciences Inc. (SLDB)
Solid Biosciences (NASDAQ:SLDB) initiated with Sell rating and $25 (27% downside risk) price target at Citigroup citing scant market opportunity for DMD candidate SGT-001 compared to Sarepta's and Pfizer's offerings. Shares are down 1% premarket.
You need to be a member in order to leave a comment
Sign up for a new account in our community. It's easy!
Already have an account? Sign in here.
No registered users viewing this page.
Please donate to support this community. We appreciate all donations!